Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial
Abstract Purpose Concurrent chemoradiotherapy (CCRT) is a standard treatment choice for locally advanced hypopharyngeal carcinoma. The aim of this study was to investigate whether induction chemotherapy (IC) followed by CCRT is superior to CCRT alone to treat locally advanced hypopharyngeal carcinom...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-10306-y |
| _version_ | 1811315395779362816 |
|---|---|
| author | Xi Luo Xiaodong Huang Jingwei Luo Jianping Xiao Kai Wang Yuan Qu Xuesong Chen Ye Zhang Runye Wu Jingbo Wang Jianghu Zhang Guozhen Xu Li Gao Shaoyan Liu Xiaolei Wang Xiaohui He Dehong Luo Junlin Yi |
| author_facet | Xi Luo Xiaodong Huang Jingwei Luo Jianping Xiao Kai Wang Yuan Qu Xuesong Chen Ye Zhang Runye Wu Jingbo Wang Jianghu Zhang Guozhen Xu Li Gao Shaoyan Liu Xiaolei Wang Xiaohui He Dehong Luo Junlin Yi |
| author_sort | Xi Luo |
| collection | DOAJ |
| description | Abstract Purpose Concurrent chemoradiotherapy (CCRT) is a standard treatment choice for locally advanced hypopharyngeal carcinoma. The aim of this study was to investigate whether induction chemotherapy (IC) followed by CCRT is superior to CCRT alone to treat locally advanced hypopharyngeal carcinoma. Methods and materials Patients (n = 142) were randomized to receive two cycles of paclitaxel/cisplatin/5-fluorouracil (TPF) IC followed by CCRT or CCRT alone. The primary end point was overall survival (OS). The secondary end points included the larynx-preservation rate, progression-free survival (PFS), distant metastasis-free survival (DMFS), and toxicities. Results Ultimately, 113 of the 142 patients were analyzed. With a median follow-up of 45.6 months (interquartile range 26.8–57.8 months), the 3-year OS was 53.1% in the IC + CCRT group compared with 54.8% in the CCRT group (hazard ratio, 1.004; 95% confidence interval, 0.573–1.761; P = 0.988). There were no statistically significant differences in PFS, DMFS, and the larynx-preservation rate between the two groups. The incidence of grade 3–4 hematological toxicity was much higher in the IC+ CCRT group than in the CCRT group (54.7% vs. 10%, P < 0.001). Conclusions Adding induction TPF to CCRT did not improve survival and the larynx-preservation rate in locally advanced hypopharyngeal cancer, but caused a higher incidence of acute hematological toxicities. Trial registration ClinicalTrials.gov , number NCT03558035. Date of first registration, 15/06/2018. |
| first_indexed | 2024-04-13T11:30:42Z |
| format | Article |
| id | doaj.art-518dec86917f4d4ba3687be88c3c38d4 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-13T11:30:42Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-518dec86917f4d4ba3687be88c3c38d42022-12-22T02:48:35ZengBMCBMC Cancer1471-24072022-11-0122111010.1186/s12885-022-10306-yInduction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trialXi Luo0Xiaodong Huang1Jingwei Luo2Jianping Xiao3Kai Wang4Yuan Qu5Xuesong Chen6Ye Zhang7Runye Wu8Jingbo Wang9Jianghu Zhang10Guozhen Xu11Li Gao12Shaoyan Liu13Xiaolei Wang14Xiaohui He15Dehong Luo16Junlin Yi17Department of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Purpose Concurrent chemoradiotherapy (CCRT) is a standard treatment choice for locally advanced hypopharyngeal carcinoma. The aim of this study was to investigate whether induction chemotherapy (IC) followed by CCRT is superior to CCRT alone to treat locally advanced hypopharyngeal carcinoma. Methods and materials Patients (n = 142) were randomized to receive two cycles of paclitaxel/cisplatin/5-fluorouracil (TPF) IC followed by CCRT or CCRT alone. The primary end point was overall survival (OS). The secondary end points included the larynx-preservation rate, progression-free survival (PFS), distant metastasis-free survival (DMFS), and toxicities. Results Ultimately, 113 of the 142 patients were analyzed. With a median follow-up of 45.6 months (interquartile range 26.8–57.8 months), the 3-year OS was 53.1% in the IC + CCRT group compared with 54.8% in the CCRT group (hazard ratio, 1.004; 95% confidence interval, 0.573–1.761; P = 0.988). There were no statistically significant differences in PFS, DMFS, and the larynx-preservation rate between the two groups. The incidence of grade 3–4 hematological toxicity was much higher in the IC+ CCRT group than in the CCRT group (54.7% vs. 10%, P < 0.001). Conclusions Adding induction TPF to CCRT did not improve survival and the larynx-preservation rate in locally advanced hypopharyngeal cancer, but caused a higher incidence of acute hematological toxicities. Trial registration ClinicalTrials.gov , number NCT03558035. Date of first registration, 15/06/2018.https://doi.org/10.1186/s12885-022-10306-yHypopharyngeal cancerConcurrent chemoradiotherapyInduction chemotherapyMulti-disciplinary treatmentLaryngeal preservation |
| spellingShingle | Xi Luo Xiaodong Huang Jingwei Luo Jianping Xiao Kai Wang Yuan Qu Xuesong Chen Ye Zhang Runye Wu Jingbo Wang Jianghu Zhang Guozhen Xu Li Gao Shaoyan Liu Xiaolei Wang Xiaohui He Dehong Luo Junlin Yi Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial BMC Cancer Hypopharyngeal cancer Concurrent chemoradiotherapy Induction chemotherapy Multi-disciplinary treatment Laryngeal preservation |
| title | Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial |
| title_full | Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial |
| title_fullStr | Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial |
| title_full_unstemmed | Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial |
| title_short | Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: a preliminary analysis of a randomized phase 2 trial |
| title_sort | induction tpf followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer a preliminary analysis of a randomized phase 2 trial |
| topic | Hypopharyngeal cancer Concurrent chemoradiotherapy Induction chemotherapy Multi-disciplinary treatment Laryngeal preservation |
| url | https://doi.org/10.1186/s12885-022-10306-y |
| work_keys_str_mv | AT xiluo inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT xiaodonghuang inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT jingweiluo inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT jianpingxiao inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT kaiwang inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT yuanqu inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT xuesongchen inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT yezhang inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT runyewu inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT jingbowang inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT jianghuzhang inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT guozhenxu inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT ligao inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT shaoyanliu inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT xiaoleiwang inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT xiaohuihe inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT dehongluo inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial AT junlinyi inductiontpffollowedbyconcurrentchemoradiotherapyversusconcurrentchemoradiotherapyaloneinlocallyadvancedhypopharyngealcancerapreliminaryanalysisofarandomizedphase2trial |